Angiotensin-converting enzyme (ACE) inhibitors can be used to prevent the development of radiation nephropathy. Current studies were designed to determine whether blocking the angiotensin II (AII) receptor, rather than preventing the creation of AII, would be effective in the prophylaxis of radiation nephropathy. Rats received 17 Gy total-body irradiation (TBI) in six fractions followed by syngeneic bone marrow transplantation (BMT). Prior to TBI the rats were randomized to groups receiving an ACE inhibitor (captopril), an AII type 1 ( AT1) receptor antagonist (L-158,809) or no treatment. Renal function was assessed over 40 weeks, and a subset of animals were sacrificed for histopathology at 33 weeks. Renal function deteriorated progressively in animals receiving TBI alone, leading to renal failure by 34 weeks. Renal function was significantly better in animals receiving either captopril or L-158,809, and none of these animals had progressed to renal failure by 43 weeks. Analysis of both renal function and histopathology shows that the AII receptor antagonist is more effective than the ACE inhibitor in the prophylaxis of BMT nephropathy. This indicates that a reduction of activation of the AT1 receptor by AII, by itself, is sufficient for the prophylaxis of radiation nephropathy.
Skip Nav Destination
Research Article| July 01 1996
Angiotensin II Receptor Antagonists in the Prevention of Radiation Nephropathy
John E. Moulder ;
Brian L. Fish ;
Eric P. Cohen ;
Radiat Res (1996) 146 (1): 106–110.
- Views Icon Views
- Share Icon Share
- Search Site
John E. Moulder, Brian L. Fish, Eric P. Cohen, Stephen M. Bonsib; Angiotensin II Receptor Antagonists in the Prevention of Radiation Nephropathy. Radiat Res 1 July 1996; 146 (1): 106–110. doi: https://doi.org/10.2307/3579403
Download citation file:
Citing articles via
Commonalities Between COVID-19 and Radiation Injury
Carmen I. Rios, David R. Cassatt, Brynn A. Hollingsworth, Merriline M. Satyamitra, Yeabsera S. Tadesse, Lanyn P. Taliaferro, Thomas A. Winters, Andrea L. DiCarlo
Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development
Ziad Francis, Sebastien Incerti, Sara A. Zein, Nathanael Lampe, Carlos A. Guzman, Marco Durante
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
Pataje G. Prasanna, Gayle E. Woloschak, Andrea L. DiCarlo, Jeffrey C. Buchsbaum, Dörthe Schaue, Arnab Chakravarti, Francis A. Cucinotta, Silvia C. Formenti, Chandan Guha, Dale J. Hu, Mohammad K. Khan, David G. Kirsch, Sunil Krishnan, Wolfgang W. Leitner, Brian Marples, William McBride, Minesh P. Mehta, Shahin Rafii, Elad Sharon, Julie M. Sullivan, Ralph R. Weichselbaum, Mansoor M. Ahmed, Bhadrasain Vikram, C. Norman Coleman, Kathryn D. Held
Germicidal Efficacy and Mammalian Skin Safety of 222-nm UV Light
Manuela Buonanno, Brian Ponnaiya, David Welch, Milda Stanislauskas, Gerhard Randers-Pehrson, Lubomir Smilenov, Franklin D. Lowy, David M. Owens, David J. Brenner
RITCARD: Radiation-Induced Tracks, Chromosome Aberrations, Repair and Damage
Ianik Plante, Artem Ponomarev, Zarana Patel, Tony Slaba, Megumi Hada